GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Gross-Profit-to-Asset %

Tryptamine Therapeutics (ASX:TYP) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Tryptamine Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Tryptamine Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was A$4.48 Mil. Therefore, Tryptamine Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Tryptamine Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Tryptamine Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Gross-Profit-to-Asset % Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - - 0.57 6.35

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - 7.00 7.85 -

Competitive Comparison of Tryptamine Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Tryptamine Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tryptamine Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Gross-Profit-to-Asset % falls into.



Tryptamine Therapeutics Gross-Profit-to-Asset % Calculation

Tryptamine Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0.619/( (13.614+5.881)/ 2 )
=0.619/9.7475
=6.35 %

Tryptamine Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (5.881+3.083)/ 2 )
=0/4.482
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Tryptamine Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics (ASX:TYP) Business Description

Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines